A real-world, multicenter, 52-week prospective cohort study to capture the reasons for switch to triple combination therapy and to assess the clinical and patient reported outcomes in adults with moderate to severe COPD treated with Trixeo Aerosphere™ in routine care settings in Greece.
Pulmonary Disease, Chronic Obstructive (COPD)
40 Years - 80 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Aug 2023 by AstraZeneca
No locations available